Drugs · acquisition-cost intelligence
ALYACEN 1/35
norethindrone and ethinyl estradiol· ingredient ethinyl estradiolEstren derivatives
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.20508
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other ethinyl estradiol products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| ALTAVERA | $0.13489 | −$0.07020 |
| Azurette | $0.15038 | −$0.05470 |
| Aurovela 1/20 | $0.16969 | −$0.03540 |
| Afirmelle | $0.19856 | −$0.00650 |
| Cryselle | $0.29910 | +$0.09400 |
| Balziva | $0.29967 | +$0.09460 |
| ALYACEN 1/35 | $0.30451 | +$0.09940 |
| Aurovela 1.5/30 | $0.34554 | +$0.14050 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.